DEA Labels Lab Buzz as Cannabimimetic Schedule I Threats
Published Date: 1/20/2026
Rule
Summary
Starting February 19, 2026, the DEA is officially defining “cannabimimetic agents” and adding 18 new substances to this group, all still Schedule I drugs. They’re also simplifying things by giving most of these substances one single drug code, making tracking easier. This update affects manufacturers, law enforcement, and anyone handling these substances, but it won’t change their legal status or cause new fees.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 1 costs, 1 mixed.
Eighteen substances formally listed
Starting February 19, 2026, DEA adds 18 additional named substances to the definition of “cannabimimetic agents.” All 18 substances remain Schedule I controlled substances, so their legal schedule status does not change.
Single DEA drug code for most agents
DEA consolidates most existing administration controlled substances codes for cannabimimetic agents into a single drug code number 7000 when the rule takes effect on February 19, 2026, to simplify tracking and reporting.
Two substances moved but keep existing codes
JWH-018 and AM2201 are moved to 21 CFR 1308.11(d) but retain their existing drug codes (7118 and 7201) to facilitate quota and international reporting; upon that move, positional isomers of these two substances will be defined as Schedule I controlled substances.
No new fees or reporting obligations
DEA states this final rule does not change the Schedule I status of listed substances, does not impose new regulatory controls, recordkeeping, reporting requirements, or information-collection burdens, and will not create new fees for handlers.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2026-00904, Commercial Non-Power Production or Utilization Facilities
The Nuclear Regulatory Commission just clarified that commercial non-power nuclear facilities must follow certain safety update rules, while non-commercial ones don’t. This change kicks in right away and affects businesses running these facilities, who now have 30 days to share their thoughts. No new fees are mentioned, but staying in the loop is key to avoid surprises!
Next: 2026-00909, Allocation of Assets in Single-Employer Plans; Interest Assumptions for Valuing Benefits
Starting January 31, 2026, new rules change how single-employer pension plans calculate the value of benefits when plans end. These updated interest assumptions affect plan sponsors and the Pension Benefit Guaranty Corporation, helping make sure money values match real market prices. If you’re involved with these plans, expect more accurate numbers for payouts and possible impacts on withdrawal costs.